Disclosure of Payments to Healthcare Professionals
Our collaborations with healthcare professionals always aim to benefit patients, improve medical practices and patient care.
Activities can range from clinical research to exchanges on how new medicines fit into patient pathway.
We believe that a more open transparent relationship strengthens the basis for collaboration and is in the best interest of patients and all health stakeholders.
For this reason, we are committed to disclose our interactions with healthcare professionals and organizations through the Disclosure Code de l’EFPIA.
Austria
Public disclosure 2022, 2023, 2024
Bulgaria
Public disclosure 2022 , 2023, 2024
Croatia
Public disclosure 2023,
No Transfer of Value in 2022, 2024
Cyprus
Public disclosure 2022, 2023, 2024
Czech Republic
Public disclosure 2022 , 2023, 2024
Denmark
Public disclosure 2022 , 2023, 2024
Finland
Public disclosure 2022 , 2023, 2024
Greece
Report PFD 2022 / Report PFD 2023 / Report PFD 2024
Pierre Fabre Corporate Greek Crossborder 2022 / Pierre Fabre Corporate Greek Crossborder 2023 / Pierre Fabre Corporate Greek Crossborder 2024
Report PFMS 2022/ Report PFMS 2023 / Report PFMS 2024
Hungary
Public disclosure 2022, 2023, 2024
Luxembourg
Public disclosure 2022, 2023, 2024
No transfer of Value in 2021,
Norway
Public disclosure 2022 , 2023, 2024
Poland
Public disclosure HCP 2022, 2023
Public disclosure HCO 2022
No Transfer of Value in 2023
Public disclosure R&D 2022 , 2023
Public disclosure report 2024
Slovak republic
Public disclosure 2022 , 2023, 2024,
Serbia
Public disclosure 2022, 2023, 2024
No Transfer of Value in 2021
Sweden
Public disclosure 2022, 2023, 2024
Switzerland
Public disclosure 2022, 2023, 2024
DISCLOSURE METHODOLOGY PIERRE FABRE PHARMACEUTICALS TOV 2025
- The publication provided through this section is made in accordance with the Company Self-Certification 2025 .
-
Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by e-mail: transparency.compliance@pierre-fabre.com